Can Low-Dose Interferon Prevent Relapse of Hepatitis C Virus Infection?
Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals. Low-dose oral interferon may reduce the risk of HCV relapse in patients with mild liver fibrosis according to a study published in the Journal of Interferon & Cytokine Research.
In "A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse," Chuan-Mo Lee and coauthors from several universities and hospitals in Taiwan present the results of a clinical trial comparing the effects of 24 weeks of treatment with two doses of oral interferon-alpha or placebo in patients who achieved viral clearance after successful HCV therapy.
"This is a highly significant study relevant to the optimal use of IFN for HCV treatment," says co-editor-in-chief Ganes C. Sen, PhD, chairman of the Department of Molecular Genetics at the Cleveland Clinic Foundation in Ohio.
Source: International Cytokine and Interferon Society, Mary Ann Liebert, Inc.
The CDC at a Crossroads: Budget Cuts, Public Health, and the Growing Threat of Infectious Diseases
March 12th 2025Budget cuts to the CDC threaten disease surveillance, outbreak response, and public health programs, increasing risks from measles, avian flu, and future pandemics while straining health care infrastructure nationwide.
Standing Up for Science: A Rally Participant’s Perspective
March 11th 2025Infection Control Today's Editorial Advisory Board member and contributing editor, Heather Stoltzfus, MPH, RN, CIC, recently joined the Stand Up for Science rally in Washington, DC. She gives a first-person perspective on the rally and the rally-goers' strong message.
